Lee Kalowski Sells 3,995 Shares of Q32 Bio (NASDAQ:QTTB) Stock

Q32 Bio Inc. (NASDAQ:QTTB) CFO Lee Kalowski sold 3,995 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $4.51, for a total value of $18,017.45. Following the completion of the sale, the chief financial officer directly owned 35,943 shares of the company’s stock, valued at approximately $162,102.93. This trade represents a 10.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Lee Kalowski also recently made the following trade(s):

• On Tuesday, December 2nd, Lee Kalowski sold 9,072 shares of Q32 Bio stock. The shares were sold at an average price of $3.46, for a total value of $31,389.12.

Q32 Bio Trading Down 4.2%

Shares of Q32 Bio stock opened at $4.56 on Friday. The company has a market capitalization of $56.09 million, a P/E ratio of -1.33 and a beta of 0.16. The stock has a fifty day simple moving average of $3.81 and a 200 day simple moving average of $2.90. Q32 Bio Inc. has a 12-month low of $1.35 and a 12-month high of $6.37.

Q32 Bio News Summary

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $13 price target, providing a long‑term constructive view that can support upside versus current levels. HC Wainwright Begins Coverage on Q32 Bio
• Neutral Sentiment: HC Wainwright published a multi‑year forecast showing improving EPS over time and an eventual transition to modest profitability in FY2030 (EPS $0.11), which is a positive directional signal but depends on successful clinical and commercial execution.
• Negative Sentiment: The analyst model shows substantial near‑term losses: Q4 2025 EPS of ($0.63) and FY2025–FY2028 EPS ranging from about ($2.91) to ($2.19). These projected deficits increase financing and execution risk and likely weigh on short‑term investor sentiment.
• Negative Sentiment: Consensus full‑year earnings remain deeply negative (current consensus ~($12.32) per share), indicating the market and other analysts expect much larger near‑term losses than HC Wainwright’s more optimistic runway—this divergence may temper the impact of the Buy rating.

Analysts Set New Price Targets

A number of research firms recently weighed in on QTTB. HC Wainwright started coverage on shares of Q32 Bio in a research report on Wednesday. They set a “buy” rating and a $13.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Q32 Bio in a research note on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $14.00.

Hedge Funds Weigh In On Q32 Bio

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Monaco Asset Management SAM increased its holdings in Q32 Bio by 17.1% during the second quarter. Monaco Asset Management SAM now owns 591,937 shares of the company’s stock worth $882,000 after buying an additional 86,486 shares during the last quarter. Geode Capital Management LLC boosted its stake in Q32 Bio by 19.9% in the fourth quarter. Geode Capital Management LLC now owns 106,113 shares of the company’s stock valued at $352,000 after acquiring an additional 17,617 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Q32 Bio by 110.6% during the 4th quarter. Renaissance Technologies LLC now owns 99,600 shares of the company’s stock valued at $331,000 after acquiring an additional 52,300 shares during the period. Jane Street Group LLC purchased a new stake in shares of Q32 Bio during the 4th quarter worth approximately $84,000. Finally, HRT Financial LP increased its stake in shares of Q32 Bio by 66.5% during the 4th quarter. HRT Financial LP now owns 24,698 shares of the company’s stock worth $81,000 after purchasing an additional 9,862 shares during the last quarter. 31.32% of the stock is owned by hedge funds and other institutional investors.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.